Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) plus pembrolizumab (pembro) plus carboplatin (carbo) +/- bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC)

Vergote, IgnaceMirza, Mansoor RazaSehouli, JalidLorusso, DomenicaOse, Fatih K.Cibula, DavidWestermann, Anneke M.Collins, Dearbhaile CatherineBanerjee, Susana N.Oaknin, AnaSoumaoro, IbrahimaJain, ShwetaMonk, Bradley J.2022-11-042022-11-0420220732-183Xhttp://hdl.handle.net/11727/8010enginfo:eu-repo/semantics/closedAccessTrial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) plus pembrolizumab (pembro) plus carboplatin (carbo) +/- bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC)conferenceObject4016000863680305002